Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Investments (2017 - 2025)

Syndax Pharmaceuticals (SNDX) has disclosed Long-Term Investments for 5 consecutive years, with $20.1 million as the latest value for Q3 2025.

  • For Q3 2025, Long-Term Investments rose 100.88% year-over-year to $20.1 million; the TTM value through Sep 2025 reached $20.1 million, up 100.88%, while the annual FY2024 figure was $119.5 million, 300.68% up from the prior year.
  • Long-Term Investments hit $20.1 million in Q3 2025 for Syndax Pharmaceuticals, down from $62.6 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $119.5 million in Q4 2024 and bottomed at $5.5 million in Q4 2022.
  • Average Long-Term Investments over 4 years is $39.9 million, with a median of $20.1 million recorded in 2025.
  • Year-over-year, Long-Term Investments surged 445.42% in 2023 and then crashed 36.14% in 2024.
  • Syndax Pharmaceuticals' Long-Term Investments stood at $5.5 million in 2022, then soared by 445.42% to $29.8 million in 2023, then surged by 300.68% to $119.5 million in 2024, then tumbled by 83.14% to $20.1 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $20.1 million, $62.6 million, and $89.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.